Press release
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
There was no significant difference in decision regret levels among those receiving a low- (Class 1A), intermediate- (Class 1B) or high-risk (Class 2)
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nThere was no significant difference in decision regret levels among those receiving a low- (Class 1A), intermediate- (Class 1B) or high-risk (Class 2) DecisionDx-UM test result\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study completed in collaboration with the Melanoma Research Foundation (MRF) in which most patients diagnosed with uveal melanoma (UM) indicated their desire for prognostic testing at diagnosis, reported finding value in their test result and experienced lower decision regret, regardless of whether their test result indicated that their UM tumor was at a high or low risk of metastasis. The study, titled “Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling,” was published in Melanoma Management and can be viewed on Castle's website.\n\n“We were excited to embark on this collaboration with Castle Biosciences, a leader in prognostic testing for uveal melanoma, as few studies have explored patients’ perspectives towards prognostic testing and the value patients can gain by having personalized prognostic information,” said Kyleigh LiPira, M.B.A., chief executive officer of the MRF. “The more information patients can have in advance of making treatment decisions is critical to having successful outcomes. This data further reinforces the need for patients to understand their options so they can be active participants in their care.”\n\nThe study aimed to assess patient experiences with DecisionDx®-UM testing and other prognostic methods through an online questionnaire that was distributed by the MRF’s CURE OM initiative. CURE OM (the Community United for Research and Education of Ocular Melanoma) is the MRF’s initiative to increase awareness, education and research funding for ocular melanoma, while improving the lives of people affected by this disease. The questionnaire captured anonymized information regarding patients’ experiences with prognostic testing following a diagnosis of UM; 177 patients completed the survey.\n\nHighlights from the study include the following:\n\n\n90% of respondents reported wanting prognostic information at the time of diagnosis.\n\n\n99% of respondents who had prognostic testing performed with D...